Remepy Launches with $15 Million in Funding To Bring First Hybrid Drug To Market

NEW YORK--(BUSINESS WIRE)--Remepy, a pioneer in “hybrid drugs,” today announced that it has successfully closed a $10M seed investment round, which together with earlier funding totals $15M. The round was led by NFX, joined by Vine Ventures, PsyMed Ventures, Supernode Ventures and Firstime Ventures, joining previous pre-seed lead investor TechAviv as well as Fresh.fund, Samsung Next, StageNext Fund and 97212 Ventures. Remepy’s new hybrid drugs combine traditional drugs with its “digital molecul